全文获取类型
收费全文 | 1700篇 |
免费 | 137篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 91篇 |
妇产科学 | 28篇 |
基础医学 | 282篇 |
口腔科学 | 13篇 |
临床医学 | 156篇 |
内科学 | 540篇 |
皮肤病学 | 15篇 |
神经病学 | 103篇 |
特种医学 | 59篇 |
外科学 | 152篇 |
综合类 | 23篇 |
预防医学 | 209篇 |
眼科学 | 13篇 |
药学 | 65篇 |
肿瘤学 | 80篇 |
出版年
2022年 | 15篇 |
2021年 | 20篇 |
2020年 | 14篇 |
2019年 | 20篇 |
2018年 | 23篇 |
2017年 | 23篇 |
2016年 | 26篇 |
2015年 | 29篇 |
2014年 | 35篇 |
2013年 | 47篇 |
2012年 | 61篇 |
2011年 | 61篇 |
2010年 | 54篇 |
2009年 | 33篇 |
2008年 | 69篇 |
2007年 | 66篇 |
2006年 | 77篇 |
2005年 | 71篇 |
2004年 | 60篇 |
2003年 | 60篇 |
2002年 | 50篇 |
2001年 | 70篇 |
2000年 | 59篇 |
1999年 | 47篇 |
1998年 | 25篇 |
1997年 | 18篇 |
1996年 | 18篇 |
1995年 | 22篇 |
1994年 | 9篇 |
1993年 | 14篇 |
1992年 | 32篇 |
1991年 | 42篇 |
1990年 | 41篇 |
1989年 | 53篇 |
1988年 | 40篇 |
1987年 | 42篇 |
1986年 | 41篇 |
1985年 | 39篇 |
1984年 | 20篇 |
1983年 | 28篇 |
1982年 | 16篇 |
1981年 | 19篇 |
1980年 | 22篇 |
1979年 | 17篇 |
1978年 | 19篇 |
1976年 | 13篇 |
1975年 | 15篇 |
1974年 | 16篇 |
1973年 | 17篇 |
1972年 | 11篇 |
排序方式: 共有1843条查询结果,搜索用时 375 毫秒
71.
Herniorrhaphy. A personal experience with 6,321 cases 总被引:10,自引:0,他引:10
I L Lichtenstein 《American journal of surgery》1987,153(6):553-559
The results of 6,321 consecutive herniorrhaphies have been reported. Over 20 percent of the cases were referred recurrences when first seen. Ninety-one percent of the patients were followed from 2 to 14 years, with an overall recurrence rate of 0.7 percent. A low recurrence rate was not unfavorably affected by the prompt resumption of activity postoperatively. Some recurrences are unavoidable; however, it is essential to accept the dictum that all hernias can be cured. 相似文献
72.
73.
BackgroundNational Institute for Health and Clinical Excellence guidelines (CG87) recommend neutral protamine hagedorn (NPH) insulin for the provision of basal insulin in type 2 diabetes, but use of analogue insulin is as much as 40%. Where residual endogenous insulin secretory capacity is present there is no evidence that analogue insulins provide any additional benefit over human insulins, and they come at an expensive premium. Anecdotally, however, there is a reluctance to switch people back to NPH insulin, partly because of a perceived risk of pancreatic failure and potential ketosis. Urinary C-peptide creatinine ratio (UCPCR) has been validated as a method for evaluating residual endogenous insulin secretion in type 1 and type 2 diabetes, with a UCPCR of no more than 0·2 nmol/mmol suggestive of absolute insulin deficiency. We aimed to evaluate the prevalence of true insulin deficiency among patients with type 2 diabetes with UCPCR, and confirm findings with the gold standard mixed meal tolerance test (MMTT).Methods191 insulin-treated patients with a clinical diagnosis of type 2 diabetes (diagnosed at or after age 45 years and who did not start insulin within the first year of diagnosis) collected a 2-h post-prandial urine sample for UCPCR measurement. Nine patients from two subgroups (UCPCR ≤0·2 nmol/mmol and UCPCR >0·2) completed a standard MMTT.Findings11 (5·8%) of 191 patients had two consistent UCPCRs of less than or equal to 0·2 nmol/mmol. Nine were able to do the MMTT, of whom five were confirmed to have absolute insulin deficiency (stimulated serum c-peptide <0·2 nmol/L). Three of these five patients were glutamic acid decarboxylase antibody-negative. Nine of nine patients with UCPCR of more than 0·2 nmol/L had confirmed endogenous insulin secretion in their MMTT. Those with insulin deficiency had a shorter time to starting insulin (median 2·5 years [IQR 1·5–3·0] vs 6·0 [3·0–10·75], p=0·005) and lower body-mass index (25 kg/m2 vs 29, p=0·04) but no other significant differences in clinical characteristics.InterpretationWe have demonstrated a very low prevalence of true pancreatic failure in this population of insulin-treated patients with type 2 diabetes. This requires further exploration by comparison of a population being treated with NPH insulin with one on analogue insulin, and then determining whether UCPCR could act as a clinical decision support tool to safely switch from analogue insulin to NPH insulin.FundingNational Institute for Health Research. 相似文献
74.
75.
76.
77.
Linda S Lindstr?m Benjamin Yip Paul Lichtenstein Yudi Pawitan Kamila Czene 《Cancer epidemiology, biomarkers & prevention》2007,16(8):1639-1643
BACKGROUND: Melanoma and squamous cell carcinoma of the skin (SCC) have been previously shown to coaggregate in families. To shed light on the etiology, we estimated the relative contributions of genetic and environmental factors on the occurrence of each disease, in addition to their influence on coaggregation of the two diseases. Because the malignancies are dependent on UV radiation, we did separate analyses for sun-covered and sun-exposed sites. METHODS: Our Swedish population-based data included 11 million individuals in 3 million families. We used an extended generalized linear mixed model to estimate the genetic and environmental contribution. RESULTS: In melanoma, the genetic contribution was 18% [95% confidence interval (95% CI), 13-22%] in the all-sites analysis, whereas the family-shared contribution was slightly higher in the sun-covered compared with sun-exposed sites analysis. SCC revealed very similar estimates in all analyses for both the genetic effects estimated to 8% (95% CI, 4-12%) and family-shared environmental factors at 18% (95% CI, 16-19%), respectively. In the coaggregation analysis, genetic and family-shared environmental components were estimated at 47% (95% CI, 43-51%) and 36% (95% CI, 33-39%), respectively. CONCLUSIONS: Genetic factors are important in familial aggregation of melanoma and the higher sun-covered compared with sun-exposed site estimate of family-shared environment may convey benefit from cautious sunbathing. In SCC, we observed the highest contribution of family-shared environmental effects in cancer to date, implicating the importance of familial habits. Moreover, we elucidate the potential involvement of genetic variability in the familial coaggregation of melanoma and SCC. 相似文献
78.
79.
Tham TC Lichtenstein DR Vandervoort J Wong RC Slivka A Banks PA Yim HB Carr-Locke DL 《The American journal of gastroenterology》2000,95(4):956-960
OBJECTIVE: Obstruction of the main pancreatic duct from malignancy with secondary ductal hypertension may be an important contributor to pain. The aim of our study was to determine the efficacy and safety of pancreatic stent placement for patients with "obstructive" pain due to pancreatic malignancy. METHODS: Pancreatic duct stents were placed in 10 consecutive patients with malignant pancreatic duct obstruction and abdominal pain. Seven patients had "obstructive" type pain and three had chronic unremitting pain. Nine had primary pancreatic ductal adenocarcinoma and one had metastatic melanoma. There were eight women and two men. Mean age was 61 yr (range, 47-80 yr). All patients had dominant main pancreatic duct strictures with proximal dilation. Tumors were unresectable. All patients took potent analgesics before endoscopic stent therapy. Polyethylene pancreatic stents, 5- and 7-French, were successfully placed in seven patients, and self-expanding metallic stents were successfully placed in three patients. RESULTS: There were no procedure-related complications. One patient required a single repeat examination to replace a migrated stent. Seven patients (75%) experienced a reduction in pain. Analgesia was no longer required in five (50%). Three patients who did not improve had chronic pain rather than "obstructive" pain. CONCLUSIONS: Pancreatic stent placement for patients with "obstructive" pain secondary to a malignant pancreatic duct stricture appears to be safe and effective. It should be considered as a therapeutic option in these patients. It does not seem to be effective for chronic unremitting pain. 相似文献
80.